Tag: FDA-approved gynecologic oncology drugs

Home / FDA-approved gynecologic oncology drugs

Categories

Tisotumab vedotin-tftv is approved by the FDA for recurrent or metastatic cervical cancer

April 2024: Tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) has received formal approval from the Food and Drug Administration for the treatment of recurrent or metastatic cer...
fda-approved-gynecologic-oncology-drugs

Scan the code